Shares in Australian pharmaceutical firm QRxPharma have plummeted 80 per cent in a major shareholder revolt after the company failed to win US regulatory approval for its painkiller Moxduo.
Subscribe to gift this article
Gift 5 articles to anyone you choose each month when you subscribe.
Subscribe nowAlready a subscriber?
Shares in Australian pharmaceutical firm QRxPharma have plummeted 80 per cent in a major shareholder revolt after the company failed to win regulatory approval for its painkiller drug, Moxduo, to be released in the United States.
QRxPharma shares are trading around 13¢, down from 70¢ on April 17 and 12.5 per cent below where they were at the start of this year.
Fetching latest articles
Original URL: https://www.afr.com/companies/healthcare-and-fitness/qrxpharma-drops-80pc-after-us-rejects-great-drug-20140423-i4bfd
